ONCO
ONCO
NASDAQ · Biotechnology

Onconetix Inc

$3.03
-0.73 (-19.41%)
Financial Highlights (FY 2026)
Revenue
24.25M
Net Income
-417,296,962
Gross Margin
77.6%
Profit Margin
-1,721.0%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 77.6% 47.7% 47.7% 47.7%
Operating Margin -2,874.5% 21.1% 17.6% 19.8%
Profit Margin -1,721.0% 12.8% 15.1% 11.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 24.25M 335.8K 347.3K 304.4K
Gross Profit 18.82M 160.1K 165.5K 145.1K
Operating Income -696,998,957 70.8K 61.3K 60.4K
Net Income -417,296,962 43.0K 52.4K 35.7K
Gross Margin 77.6% 47.7% 47.7% 47.7%
Operating Margin -2,874.5% 21.1% 17.6% 19.8%
Profit Margin -1,721.0% 12.8% 15.1% 11.7%
Rev Growth — +0.6% +12.6% -7.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 556.4K 513.3K 557.3K
Total Equity — 947.6K 993.8K 1.02M
D/E Ratio — 0.59 0.52 0.55
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -696,548,135 73.2K 78.8K 66.7K
Free Cash Flow — 45.7K 64.8K 36.1K